Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Free fatty acid receptor 3 |
| Gene Name | FFAR3 |
| Uniprot | O14843 (Human); Q3UFD7 (Mouse) |
| Synonym | FFA3R; GPR41; GPR42; G-protein coupled receptor 41 |
| Background | FFAR3, also known as G-protein coupled receptor 41 (GPR41), is a 38.6 kDa G protein-coupled receptor that consists of 346 amino acids. In humans, it is encoded by the FFAR3 gene which is located at the chromosome of 19q13.12. It is shown that FFAR3 is expressed in enteroendocrine cells, and the recent report also found it present in sympathetic neurons of the superior cervical ganglion. It is a protein-coding gene and its related pathways are peptide ligand-binding receptors and signals by G protein-coupled receptor. FFAR3 is activated by short-chain fatty acids (SCFAs), which engage the epigenetic regulation of inflammatory reactions via free fatty acid receptors (FFARs) and other SCFAs. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX276 | NativeExtract™ Human FFAR3 Membrane Protein (Full length, Super Nanodisc) | HEK293 cells | Full length | Native Nanodisc |
| MPX3405K | MemDX™ Membrane Protein Human FFAR3 Expressed in vitro E.coli expression system, Full Length | E.coli cell-free | Full length | Detergent |
| MP0365X | MemDX™ Membrane Protein Human FFAR3 (Free fatty acid receptor 3) for Antibody Discovery | Wheat germ cell-free | Full length | Liposome |
| Please for more products or customization | ||||
Z**e: Ideal for in vitro signaling studies. Reliable quality with batch-specific COA.
07/May/2023
J**e: Custom FFAR3 with His-tag delivered in 4 weeks.
12/Nov/2023
We provide tailored solutions to meet your specific requirements. Please for more services.
Creative Biolabs offers gene editing services. FFAR3 (Free Fatty Acid Receptor 3), a G protein-coupled receptor integral to short-chain fatty acid signaling, represents a promising target for metabolic and inflammatory disorder therapeutics. Genome editing enables precise modulation of FFAR3 expression or correction of pathogenic variants. For instance, dual RNA strategies allow targeted deletion of regulatory regions to suppress FFAR3 hyperactivity in hyperlipidemia models, restoring metabolic homeostasis. Creative Biolabs' expertise in custom RNA design and in vivo delivery systems ensures scalable solutions for preclinical validation of FFAR3-edited constructs.
Creative Biolabs offers AAV-driven overexpression constructs services. Recombinant adeno-associated virus (AAV) vectors can deliver FFAR3 overexpression cassettes to tissues with receptor deficiency. In murine colitis models, intra-colonic AAV-FFAR3 administration amplified anti-inflammatory butyrate responses, reducing mucosal damage. Creative Biolabs' optimized tropism-modified AAV serotypes enhance tissue-specific targeting, minimizing off-organ transduction. Such methodologies are pivotal for resolving FFAR3 under-expression linked to dysbiosis-associated pathologies.
Creative Biolabs offers siRNA knockdown services. RNA interference offers precise attenuation of FFAR3 overexpression in neuroendocrine tumors, where aberrant receptor activity drives hormonal hypersecretion. Lipid nanoparticle-encapsulated siRNA targeting FFAR3 mRNA suppressed tumor growth in pancreatic neuroendocrine cell xenografts by >60%. Creative Biolabs' proprietary bioinformatics pipelines identify hypervariable FFAR3 exons for allele-specific silencing, maximizing therapeutic specificity.
Creative Biolabs offers comprehensive and innovative services to drive the development of FFAR3 cell therapy. Please for more services.
Creative Biolabs offers engineered immunomodulatory cell therapies development services. Chimeric antigen receptor (CAR)-T cells engineered to secrete FFAR3 agonists modulate local immune microenvironments. In preclinical adipose tissue inflammation models, CAR-T cells releasing pentanoate activated stromal FFAR3, suppressing pro-inflammatory cytokine cascades. Creative Biolabs' integrated vector design and primary T-cell engineering platforms streamline development of such dual-function cellular therapeutics.
Creative Biolabs offers endogenous FFAR3 in stem cells development services. Upregulates endogenous FFAR3 in mesenchymal stem cells (MSCs) to enhance their immunoregulatory capacity. In graft-versus-host disease models, MSCs increased IL-10 secretion via FFAR3-mediated HDAC inhibition, improving survival rates by 40%. Creative Biolabs' non-viral delivery systems ensure stable, scarless FFAR3 activation in therapeutic cell lines.
Creative Biolabs offers microbiome-mimicking synthetic consortia development services. Co-cultures of FFAR3-expressing probiotics and primary intestinal epithelial cells replicate gut-lumen cross-talk. Encapsulated bacterial consortia producing FFAR3 ligands (e.g., propionate) restored epithelial barrier integrity in vitro, achieving 80% reduction in LPS permeability. Creative Biolabs' high-throughput microfluidics platform accelerates the development of such symbiotic therapeutic ecosystems.
The therapeutic potential of FFAR3 hinges on selecting modalities aligned with disease pathophysiology and delivery challenges. Creative Biolabs' cross-disciplinary teams provide end-to-end support—from target validation to IND-enabling studies—ensuring rapid translation of FFAR3-focused therapies. to refine your program's experimental roadmap or explore collaborative development opportunities.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
